Aggregation of human and canine platelets: modulation by purine nucleotides

Cardiovascular serotonergic system: Evolution, receptors, transporter, and function

The serotonergic system, serotonin (5HT), serotonin transporter (SERT), and serotonin receptors (5HT-x), is an evolutionarily ancient system that has clear physiological advantages to all life forms from bacteria to humans. This review focuses on the role of platelet/plasma serotonin and the cardiovascular system with minor references to its significant neurotransmitter function. Platelets transport and store virtually all plasma serotonin in dense granules. Stored serotonin is released from activated platelets and can bind to serotonin receptors on platelets and cellular components of the vascular wall to augment aggregation and induce vasoconstriction or vasodilation. The vascular endothelium is critical to the maintenance of cardiovascular homeostasis. While there are numerous ligands, neurological components, and baroreceptors that effect vascular tone it is proposed that serotonin and nitric oxide (an endothelium relaxing factor) are major players in the regulation of systemic blood pressure. Signals not fully defined, to date, that direct serotonin binding to one of the 15 identified 5HT receptors versus the transporter, and the role platelet/plasma serotonin plays in regulating hypertension within the cardiovascular system remain important issues to better understand many diseases and to develop new drugs. Also, expanded research of these pathways in lower life-forms may serve as important model systems to further our understanding of the evolution and mechanisms of action of serotonin.

Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family?

While there have been many reports investigating the biological activity and signaling mechanisms of isoprostanes, their role in biology, particularly in platelets, appears to still be underestimated. Moreover, whether these lipids have their own receptors is still debated, despite multiple reports that discrete receptors for isporpstanes do exist on platelets, vascular tissues, amongst others. This paper provides a review of the important literature of isoprostanes and provides reasoning that isoprostanes should be classified as orphan ligands until their receptor(s) is/are identified.

A study of platelets in the armadillochaetophractus villosus(xenarthra, dasypodidae)

Nothing is known about haemostasis in Xenarthra, a widely distributed Order of American mammalians. Chaetophractus villosus, a member of the Dasypodidae family of this group, which is easily adapted to captivity, is of growing interest for biomedical research. In this work, we studied platelet number, MPV, ultrastructure of the platelets by SEM and TEM, and aggregation responses to ADP and ristocetin in this species. Blood samples were obtained by cardiac puncture in 20 anaesthetised animals. Platelet count and MPV were evaluated at the beginning and at the end of a 3-year experimental period, to detect possible variations related to time of captivity. SEM and TEM were done by routine methods adapted to the material, and aggregation response to ADP and ristocetin were evaluated by the Born method. The parameters studied did not show any sex-related differences, nor did the platelet count change during captivity. Nevertheless, MPV decreased during this period. Platelets were ultrastructurally similar to those of other mammals and human beings and responded to proven agonists. Data provided in this study will contribute to the understanding of the haemostatic process in this species.

Modulation of adenine nucleotide concentrations in human plasma by erythrocytes and endothelial cells

The regulation of plasma concentrations of adenine nucleotides is unsettled. We tested the possibility of extracellular adenosine triphosphate (ATP) production from adenosine diphosphate (ADP) at physiological low concentrations by erythrocytes and endothelial cells. Filtered erythrocytes and human umbilical vein endothelial cells (HUVEC) were incubated for 15 to 120 s with ADP (10 microM), supplemented with 3H-ADP (2.85 nM) or 14C-ADP (54.6 nM). Enzymatic conversion of ADP to ATP was detected by recovery of the radioactive label in the ATP fraction. ATP was measured in the supernatant using high performance liquid chromatography (HPLC) separation, scintillation techniques, and luminometry. Using etheno (epsilon)-labeled ADP (10 microM), the extracellular localization of the conversion was further corroborated. Following ADP application in plasma, no radioactivity was detected in the ATP fraction. However, in erythrocyte suspensions, 12.9% and 9.7% of the label were recovered in the ATP fraction after application of 3H- and 14C-ADP, respectively. Between 15 and 120 s after 3H-ADP application, the 3H-ATP fraction was found to be stable at around 10%. For the range of ADP concentrations studied (10-40 microM), no saturation of ATP production was achieved. The extracellular localization of conversion was supported by the recovery of the epsilon -label in the epsilon -ATP fraction. In contrast, on HUVEC a conversion of epsilon -ADP to epsilon -ATP was not observed. In conclusion, on erythrocytes there is rapid enzymatic conversion of extracellular ADP to ATP which may play a significant role in adjusting adenine nucleotide concentrations in human plasma. In endothelial cells, extracellular conversion of ADP to ATP is of quantitatively minor importance, if it contributes at all.

Purine metabolites and malondialdehyde in platelets of diabetic patients

The concentration of some of the purine nucleotides and their metabolites together with that of malondialdehyde (MDA) have been measured in resting and stimulated platelets of type 1 and type 2 diabetic patients. While control platelets show a net decrease of guanosine triphosphate (GTP) (3.1 vs. 2.3 nmol per 10(9) platelets) and guanosine diphosphate (GDP) (3.0 vs. 2.0 nmol per 10(9) platelets) and a significant increase of adenosine (0.04 vs. 0.55 nmol per 10(9) platelets) with platelet stimulation, platelets of type 1 and type 2 diabetic patients have a lesser change of these metabolites (GTP, 2.6 vs. 2.4; GDP, 2.3 vs. 2.4; adenosine, 0.04 vs. 0.30 (P < 0.05 vs. control) nmol per 10(9) platelets in type 1 diabetics; GTP, 2.4 vs. 2.7; GDP, 2.4 vs. 2.1; adenosine, 0.08 vs. 0.32 (P < 0.05 vs. control) nmol per 10(9) platelets in type 2 diabetics). These results indicate that the change (stimulated minus resting) of GTP, GDP and adenosine in diabetic platelets is significantly different from that of controls (P < 0.001). Moreover, the amount of MDA produced during platelet activation seems to be lower than controls only in type 2 diabetes (1.81 vs. 2.86 nmol per 10(9) platelets, P < 0.05). These results seem to indicate that a difference in the pattern of platelet nucleotides could be an important feature even in well-controlled diabetes, while MDA is probably modified only in association with the late vascular complications of diabetes.

Release of adenosine triphosphate by adenosine diphosphate in whole blood and in erythrocyte suspensions

In whole blood samples from thrombocytopenic patients, large amounts of ATP were released by ADP, exceeding the level obtained with samples from normal persons by far. Because we suspected that the high potential of ATP in erythrocytes would be the main source for this phenomenon, the release of ATP by ADP was measured in whole blood samples from normal, thrombocytopenic, and leukocytopenic persons and in suspensions of washed erythrocytes. The release was recorded by a Whole Blood Lumi-Aggregometer type 500 VS (Chrono-Log Corporation, Havertown, PA) using the luciferin-luciferase system. Not only in samples from thrombocytopenic persons but also with normal platelet count, increasing amounts of ATP were released with increasing ADP concentrations, finally exceeding the ATP releasable from thrombocytes by thrombin. The amounts of ADP required to match the ATP release of thrombin were closely correlated with the platelet counts in the samples. With lower platelet counts, the release mechanism from erythrocytes could be stimulated more easily by low concentrations of ADP. The binding of ADP to platelets occurred with ostensibly higher affinity. The phenomenon of overshooting ATP release was also observed in samples from extremely leukocytopenic patients. A very large release of ATP was also achieved in suspensions of washed erythrocytes. In this way our hypothesis of ATP release from erythrocytes by ADP was confirmed again. The mechanism of the release from erythrocytes remains unclear. We speculate that its purpose is to regulate extracellular nucleotides in the circulating blood.